GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) » Definitions » EV-to-EBIT

Jacobio Pharmaceuticals Group Co (HKSE:01167) EV-to-EBIT : -0.98 (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Jacobio Pharmaceuticals Group Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jacobio Pharmaceuticals Group Co's Enterprise Value is HK$376.08 Mil. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-383.71 Mil. Therefore, Jacobio Pharmaceuticals Group Co's EV-to-EBIT for today is -0.98.

The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's EV-to-EBIT or its related term are showing as below:

HKSE:01167' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.38   Med: -3.84   Max: -0.26
Current: -1.02

During the past 6 years, the highest EV-to-EBIT of Jacobio Pharmaceuticals Group Co was -0.26. The lowest was -24.38. And the median was -3.84.

HKSE:01167's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 10.2 vs HKSE:01167: -1.02

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Jacobio Pharmaceuticals Group Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,845.43 Mil. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-383.71 Mil. Jacobio Pharmaceuticals Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -20.79%.


Jacobio Pharmaceuticals Group Co EV-to-EBIT Historical Data

The historical data trend for Jacobio Pharmaceuticals Group Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobio Pharmaceuticals Group Co EV-to-EBIT Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - -4.91 -25.33 -6.70 -4.81

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -25.33 - -6.70 - -4.81

Competitive Comparison of Jacobio Pharmaceuticals Group Co's EV-to-EBIT

For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobio Pharmaceuticals Group Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jacobio Pharmaceuticals Group Co's EV-to-EBIT falls into.



Jacobio Pharmaceuticals Group Co EV-to-EBIT Calculation

Jacobio Pharmaceuticals Group Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=376.084/-383.705
=-0.98

Jacobio Pharmaceuticals Group Co's current Enterprise Value is HK$376.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-383.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobio Pharmaceuticals Group Co  (HKSE:01167) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Jacobio Pharmaceuticals Group Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-383.705/1845.4261
=-20.79 %

Jacobio Pharmaceuticals Group Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$1,845.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jacobio Pharmaceuticals Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-383.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobio Pharmaceuticals Group Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Jacobio Pharmaceuticals Group Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobio Pharmaceuticals Group Co (HKSE:01167) Business Description

Traded in Other Exchanges
Address
No. 88, Kechuang 6th Street, Building F2, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies.
Executives
Shen Zhu 2501 Other
Treasure Partner International Limited 2501 Other
Ultimate Estate Limited 2201 Interest of corporation controlled by you
Wang Yinxiang 2501 Other
Wang Xiaojie 2307 Founder of a discretionary trust who can infl
Hu Yunyan 2501 Other
Yakovpharma Ltd 2501 Other
Willgenpharma Ltd 2501 Other
Risepharma Ltd 2101 Beneficial owner
Johwpharma Ltd 2501 Other
Hmed Ltd 2501 Other
Gloryviewpharma Ltd 2501 Other
Honourpharma Ltd 2501 Other
Blesspharma Ltd 2501 Other
Hillhouse Investment Management, Ltd. 2102 Investment manager

Jacobio Pharmaceuticals Group Co (HKSE:01167) Headlines

No Headlines